Mirati Therapeutics, Inc., a commercial stage biotechnology company, announced the Journal of Clinical Oncology published in a Rapid Communication data indicating adagrasib, a potent and selective...
Bristol Myers Squibb announced three-year follow-up results from the Phase 3 CheckMate -274 trial, demonstrating significant sustained clinical benefits with Opdivo (nivolumab) for the adjuvant...
MimiVax is pleased to announce the published manuscript of the now completed Phase IIa study of SurVaxM, a cancer vaccine, in newly diagnosed glioblastoma...
